Literature DB >> 11108328

Diffuse and severe left ventricular dysfunction induced by epicardial coronary artery spasm.

K Sakata1, R Nawada, K Ohbayashi, H Tamekiyo, H Yoshida.   

Abstract

Endothelial dysfunction and effectiveness of treatment of calcium antagonists are suggestive of coronary artery spasm as an underlying disorder in dilated cardiomyopathy (DCM). The aim of this study is to determine whether or not the epicardial coronary artery spasm can induce severe cardiac dysfunction like DCM. Thirty-four consecutive patients with angiographically normal coronary arteries and diffuse left ventricular hypokinesis whose causes had been unknown underwent acetylcholine provocation test and left ventricular biopsy. Eight patients were excluded according to the clinical and laboratory data and biopsy findings suggesting myocarditis or other systemic diseases. According to the results of the acetylcholine provocation test, 17 patients were finally diagnosed as having DCM, and nine patients (35% of the study patients), who had acetylcholine-induced diffuse and multivessel coronary spasm, were diagnosed as having DCM-like vasospastic angina pectoris (VSA). Clinical and cardiac catheterization data including hemodynamics and biopsy findings were similar between the two groups except that left ventricular end-systolic volume was significantly greater in DCM than in DCM-like VSA. After the acetylcholine provocation test, DCM patients received both a beta blocker and an angiotensin-converting enzyme inhibitor, and DCM-like VSA patients received antianginal drugs. In echocardiographic findings at predischarge and those after 6-month drug treatment, both DCM-lke VSA and DCM showed significant reduction in end-diastolic and end-systolic diameters and significant increase in fractional shortening and ejection fraction, whereas changes in ejection fraction and fractional shortening were significantly greater in DCM-like VSA than those in DCM. Epicardial coronary artery spasm can induce diffuse and severe left ventricular dysfunction like DCM in VSA. Although antianginal drugs markedly improve left ventricular function of these patients, only the acetylcholine provocation test can identify DCM-like VSA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11108328     DOI: 10.1177/000331970005101006

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  6 in total

Review 1.  Overview of the Acetylcholine Spasm Provocation Test.

Authors:  Shozo Sueda; Hiroaki Kohno; Takaaki Ochi; Tadao Uraoka
Journal:  Clin Cardiol       Date:  2015-07-14       Impact factor: 2.882

2.  Silent coronary spastic angina: A report of a case.

Authors:  Shozo Sueda; Yasuhiro Sasaki; Hirokazu Habara; Hiroaki Kohno
Journal:  J Cardiol Cases       Date:  2015-03-10

3.  Transient left ventricular dysfunction with apical ballooning (tako-tsubo cardiomyopathy) in Germany.

Authors:  Anastasios Athanasiadis; H Vogelsberg; B Hauer; G Meinhardt; S Hill; U Sechtem
Journal:  Clin Res Cardiol       Date:  2006-05-10       Impact factor: 5.460

4.  A Pilot Evaluation Study of Diffuse Coronary Arterial Contraction Causing Ischemia by Double Measurement of Left Ventriculography Before and After Intracoronary Administration of Nitrates.

Authors:  Kosuke Minai; Makoto Kawai; Kazuo Ogawa; Tomohisa Nagoshi; Satoshi Morimoto; Yasunori Inoue; Toshikazu D Tanaka; Kimiaki Komukai; Takayuki Ogawa; Michihiro Yoshimura
Journal:  Circ Rep       Date:  2021-03-19

Review 5.  Myocardial Ischemic Syndromes, Heart Failure Syndromes, Electrocardiographic Abnormalities, Arrhythmic Syndromes and Angiographic Diagnosis of Coronary Artery Spasm: Literature Review.

Authors:  Ming-Yow Hung; Nicholas G Kounis; Meng-Ying Lu; Patrick Hu
Journal:  Int J Med Sci       Date:  2020-04-27       Impact factor: 3.738

Review 6.  Role of acetylcholine spasm provocation test as a pathophysiological assessment in nonobstructive coronary artery disease.

Authors:  Satoru Suzuki; Koichi Kaikita; Eiichiro Yamamoto; Hideaki Jinnouchi; Kenichi Tsujita
Journal:  Cardiovasc Interv Ther       Date:  2020-10-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.